secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2026-09-28T12:53:56+00:00
Accession:  0001193125-26-403481
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Kodiak's Zenkuda, tabirafusp-ted hit primary endpoints in Phase 3 DAYBREAK wAMD trial; Zenkuda BLA set for 4Q2026
--------------------------------------------------------------------------------

- Zenkuda (tarcocimab tedromer) met the vision primary endpoint with p=0.0007; 54% of patients maintained 24-week dosing at year one under strict treat-to-dryness retreatment criteria.
- Tabirafusp-ted (KSI-501) met the vision primary endpoint (p=0.0036) and the anatomical key secondary endpoint (p<0.0001); both agents achieved non-inferiority vs aflibercept at year one.
- Zenkuda safety: 0% intraocular inflammation and 0.5% cataract rate (vs 0.9% for aflibercept); tabirafusp-ted showed 0.4% inflammation and 0% cataract.
- Kodiak plans a multi-indication Zenkuda BLA in 4Q2026 backed by five positive Phase 3 studies: DAYBREAK and DAYLIGHT (wAMD), GLOW and GLOW2 (diabetic retinopathy), BEACON (RVO).
- KSI-101 Phase 3 topline in macular edema secondary to inflammation (MESI) expected December 2026; tabirafusp-ted advancing in the Phase 3 ALTO program for diabetic macular edema.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000119312526403481/0001193125-26-403481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000119312526403481/d185059d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-403481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer